The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
The public benefits when new uses are found for old drugs. The benefit comes more quickly as the pharma company does not need to go through as many early studies to allow the approval for the drug use. However, I believe that pharma realizes that new uses for old drugs is not the way...
Use of Epo Stimulating Agents (ESAs) for cancer patients have all but come to a screeching halt when a plattoon of studies came out suggesting that ESAs might actually cause more harm, notably by possibly acting as a growth factor for tumor cells. Now, reserachers are trying to determine...
Transgene's TG4010 vaccine has a fairy elegant two-gene design. It appears to add benefit to a standard chemo regimen in this good-sized, randomized Phase II study for advanced lung cancer. More mature survival data will be ready by year's end. Phase III study is being planned. ...
Adding novel biologic agents (such as ASA404) to traditional chemotherapy is a very hot trend in cancer research. The data from Antisoma's lung cancer study are certainly intriguing, but again, phase II, and retrospective.
While chemo plus Avastin is the standard of care for first treatment of advanced colon cancer, chemotherapy alone is used for most early colon cancer. This large study demonstrates the relative safety of adding Avastin to chemo in the early - adjuvant – setting.
Many of us oncologists have been in the practice of continuing Herceptin (Trastuzumab) even when the breast cancer we were treating was growing while on the drug. Now, this randomized study gives data to back up that practice.
This describes a potential two-step process using modern molecular biology to customize cancer therapy. First the Affymetrix Microarray analyzes tumor genes to try to identify which patients are at high risk to have a cancer recurrence following lung cancer surgery. Second, Glaxo's MAGE-A3 proprietary...
Apparently, the FDA was not impressed enough with the data for Promacta (eltrombopag) for the treatment of ITP, a common and potentially serious auto-immune bleeding disorder involving platelets. Citing a lack of "robust evidence" from several studies, the FDA will be seeking further opinions...
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?